Biosensors International Group, Ltd
Benjamin Kern has a diverse work experience in the legal field. Benjamin is currently serving as the Associate Director Legal at Biosensors International Group, Ltd. Prior to this, they held various roles at different companies including Director Legal & Compliance at CureVac, General Counsel at Hain Lifescience GmbH, and Rechtsanwalt at Mantel Rechtsanwalt. Benjamin also worked as a Lehrbeauftragter / Adjunct Professor in Law at Duale Hochschule Baden-Württemberg and as a Wissenschaftlicher Mitarbeiter / Research Associate at an international corporate law firm.
Benjamin Kern has a diverse education history in the field of law. Benjamin completed their first state law examination, known as "1. juristische Staatsprüfung," at the University of Tübingen in an unspecified year prior to 2005. Following this, they pursued a part-time Master of Laws (LL.M.) degree at the University of Düsseldorf, which they completed in 2012. During this time, they also engaged in professional activities as they completed their second state law examination, "2. juristische Staatsprüfung," at the Oberlandesgericht Stuttgart, an esteemed higher regional court, in 2009.
In their pursuit of further specialization, Benjamin Kern enrolled at the University of Augsburg for a certification program in Compliance Officer (Univ.) and attained this qualification in 2019. Additionally, they are currently involved in a part-time doctoral program at the University of Düsseldorf, focusing on law, referred to as a "berufsbegleitende Promotion (Dr. jur.)." Details regarding the start year and anticipated completion year of this program are not specified. Overall, Benjamin Kern has demonstrated a commitment to expanding their legal expertise through their various educational undertakings in both full-time and part-time settings.
This person is not in any teams
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.